Significant Advances in Atopic Dermatitis Treatment
Atopic dermatitis is a chronic disease that disproportionately affects communities of color.
Recent studies show Dupixent has proven effective, achieving a 75% or greater improvement in overall disease severity, the primary measure, for over three-quarters of treated patients.
Patients reported substantial reductions in issues such as hyperpigmentation, dry skin, and itchiness from initial states.
These results demonstrate a strong commitment to improving clinical knowledge regarding chronic diseases in diverse populations.
Presentation Highlights at the Revolutionizing Atopic Dermatitis (RAD) Conference
In a landmark presentation, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi shared outcomes from the DISCOVER Phase 4 trial. This open-label study evaluated Dupixent in adults and adolescents suffering from moderate-to-severe atopic dermatitis, particularly focusing on patients with skin of color.
This research marks a first in clinical trials for Dupixent concerning a substantial group of patients boasting darker skin tones. Coupled with findings from previous Phase 3 trials, it supports the efficacy of Dupixent in ameliorating the signs and symptoms associated with atopic dermatitis across various skin tones.
“Atopic dermatitis is deeply rooted in type 2 inflammation and is highly prevalent among patients with skin of color,” stated Andrew Alexis, M.D., M.P.H., a Clinical Dermatology Professor at Weill Cornell Medicine. “The results indicate that individuals receiving Dupixent not only experienced a decrease in disease severity and itchiness but also improvement in specific areas such as dyspigmentation and dry skin.”
Key Findings from the DISCOVER Trial
The DISCOVER trial involved 120 participants with atopic dermatitis where 82% identified as Black, along with representatives from Asian, American Indian, Arab, and Central American backgrounds. Participants received Dupixent every two weeks following a weight-based regimen. Notable outcomes at the 24-week mark included:
- 76% of patients meeting a significant improvement in overall disease severity (EASI-75), the primary endpoint, with many seeing early results within two weeks.
- 53% demonstrated a clinically meaningful reduction in itch (?4-point improvement on the Peak-Pruritus Numerical Rating Scale [PP-NRS]).
- Post-inflammatory hyperpigmentation exhibited a 53% reduction, decreasing from an average score of 5.1 (moderate/marked) to 2.4 (mild).
- The number of patients significantly driven by dry skin reduced from 78% at baseline to 18% by the end of the trial.
Safety Profile and Clinical Relevance
The safety profile of Dupixent within the DISCOVER trial remained consistent with its previous indications. Out of 124 reported adverse events, the overall occurrence of adverse events was at 42%. The most frequently noted issues (?2%) included headache (3%), upper respiratory tract infection (2%), and allergic conjunctivitis (2%).
Understanding Atopic Dermatitis in Individuals with Skin of Color
Atopic dermatitis manifests differently among those with darker skin, leading to distinct clinical features like hardened lesions and a variance in symptoms such as itching and dyspigmentation, which can complicate diagnosis and severity assessment.
The Mechanism of Dupixent
Dupixent is a fully human monoclonal antibody developed utilizing Regeneron's proprietary VelocImmune technology. It blocks the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13), key contributors to type 2 inflammation without weakening the immune system.
This product has gained approval in over 60 countries, treating multiple conditions like asthma and chronic rhinosinusitis, demonstrating widespread application and ongoing clinical development.
As of now, Dupixent has positively impacted over 1,000,000 patients globally, showcasing its role in transforming the treatment landscape for chronic inflammatory conditions.
Future Directions and Ongoing Research
Regeneron and Sanofi continue to explore Dupixent’s efficacy in various other diseases driven by type 2 inflammation. Ongoing Phase 3 trials delve into conditions like chronic pruritus of unknown origin and bullous pemphigoid.
The extensive research and development underline the potential for Dupixent to benefit even more patients facing diverse health challenges attributable to inflammatory diseases.
Contact and Further Information
Regeneron Contacts:
Media Relations Ilana Yellen Tel: +1 914-330-9618, Email: Ilana.Yellen@regeneron.com
Investor Relations Mark Hudson, Tel: +1 914-847-3482, Email: Mark.Hudson@regeneron.com
Sanofi Contacts:
Media Relations Sandrine Guendoul, Tel: +33 6 25 09 14 25, Email: Sandrine.Guendoul@sanofi.com
Frequently Asked Questions
What is Dupixent?
Dupixent is a monoclonal antibody that treats conditions linked to type 2 inflammation, including atopic dermatitis and asthma, by inhibiting IL-4 and IL-13 pathways.
Who sponsored the DISCOVER trial?
Regeneron Pharmaceuticals, Inc. and Sanofi sponsored the DISCOVER trial to assess Dupixent's efficacy in patients with skin of color.
What were the primary outcomes of the DISCOVER trial?
Primary outcomes included a greater than 75% improvement in overall disease severity for 76% of the participants, with many experiencing benefits as early as two weeks.
Are there any notable side effects associated with Dupixent?
Common side effects include headache, injection site reactions, and upper respiratory tract infections, but these tend to be consistent with established safety profiles.
What ongoing studies are being conducted on Dupixent?
Regeneron and Sanofi are exploring Dupixent’s effectiveness in other conditions related to type 2 inflammation, which are currently in various stages of clinical trials.
